LPC
BCLI

Loeb Partners Corp’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Loeb Partners Corp’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-80
Closed -$5K – 17
2019
Q1 		$5K Sell
80
-27
-25% -$1.54K 0.1% 97
2018
Q4 		$5K Buy
+107
New +$5.27K ﹤0.01% 248

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Wolverine Trading
Wolverine Trading Chicago, Illinois $139B AUM 31.83% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Loeb Partners Corp's BCLI Position: Q2 2019 in Review

Loeb Partners Corp sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2019, closing a stake of 80 shares — an estimated $5K sold.

Loeb Partners Corp first reported a position in BCLI in Q4 2018 and held it in 2 quarters. The position peaked at $5K in Q1 2019. 37 funds tracked by Wall St. Rank hold BCLI as of Q2 2019.

  • Loeb Partners Corp reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2019 after selling out during the quarter.
  • Loeb Partners Corp sold 80 BRAINSTORM CELL THERAPUTC shares in Q2 2019, an estimated $5K.
  • Loeb Partners Corp first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2018 and held it in 2 quarters.
  • Loeb Partners Corp's BRAINSTORM CELL THERAPUTC position peaked at $5K in Q1 2019.
  • 37 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2019.

Based on Loeb Partners Corp's 13F filing for Q2 2019.